ABL Bio - medicine for A Better Life

2023

• 11

  First dosed in phase 1 clinical trial of ABL103 in Korea

• 08

  ABL103 Phase 1 clinical trial IND approved by MFDS

• 07

  Article about ABL111 published in JITC

• 03

  ABL503 Phase 1 clinical trial IND approved by MFDS

2021

• 12

  re-certified as Korea Innovative Pharmaceutical Company

• 08

  ABL501 Phase 1 clinical trial IND approved by MFDS

• 07

  Review paper on bispecific antibody-based immunotherapy published in Vaccines

• 06

  First patient dosed in Phase 1 clinical trial of ABL111

• 04

  First patient dosed in Phase 1 clinical trial of ABL503

• 03

  ABL111 phase 1 clinical trial IND approved by U.S. FDA

• 02

  ABL001 Phase 2 clinical trial IND approved by MFDS

• 01

  ABL503 Phase 1 clinical trial IND approved by U.S. FDA

• 01

  ABL's 4-1BB bispecific antibody introduced in 'Science Advances'

• 01

  ABL001 research published in International Journal of Molecular Sciences

2019

• 02

  Signs licensing agreement with WuXi Biologics

• 11

  Signs licensing agreement GenScript Biologics

• 04

  Signs licensing agreement with TSD Life Sciences

• 01

  Signs MOU with Genome & Company for development of immune checkpoint inhibitors

2017

• 08

  ABL001 Phase 1 clinical trial IND approved by MFDS

• 03

  Series B Funding (20 billion KRW)